Comparison of clinical manifestations and laboratory features between patients with AML with lower and higher LGALS3 expression
| Variables . | Total (n = 280) . | Lower LGALS3 expression (n = 140) . | Higher LGALS3 expression (n = 140) . | P value . |
|---|---|---|---|---|
| Sex* | .81 | |||
| Male | 157 | 80 (51) | 77 (49) | |
| Female | 123 | 60 (48.8) | 63 (51.2) | |
| Age (years)† | 50 (15-90) | 45.5 (15-85) | 59 (15-90) | <.001 |
| Laboratory data† | ||||
| WBC (/μL) | 23 855 (650-423 000) | 28 390 (1530-324 000) | 21 810 (650-423 000) | .051 |
| Hemoglobin (g/dL) | 8 (3.3-16.2) | 8 (3.9-13.1) | 8.1 (3.3-16.2) | .664 |
| Platelet (×1000 /μL) | 45 (3-802) | 43 (5-712) | 46 (3-802) | .746 |
| Blast (/μL) | 12 621 (0-369 070) | 17 165 (0-245 592) | 7002 (0-369 070) | .002 |
| LDH (U/L) | 882 (274-13 130) | 1005 (284-13 130) | 792 (274-8116) | .011 |
| FAB* | ||||
| M0 | 5 | 3 (60) | 2 (40) | >.999 |
| M1 | 66 | 51 (77.3) | 15 (22.7) | <.001 |
| M2 | 98 | 52 (53.1) | 46 (46.9) | .531 |
| M4 | 84 | 30 (35.7) | 54 (64.3) | .003 |
| M5 | 16 | 2 (12.5) | 14 (87.5) | .003 |
| M6 | 4 | 2 (50) | 2 (50) | >.999 |
| Undetermined | 7 | 0 (0) | 7 (100) | .014 |
| Induction response*,‡ | 211 | 120 | 91 | |
| CR | 155 | 99 (82.5) | 56 (61.5) | .001 |
| PR | 8 | 5 (4.2) | 3 (3.3) | >.999 |
| Refractory | 34 | 13 (10.8) | 21 (23.1) | .023 |
| Induction death | 14 | 3 (2.5) | 11 (12.1) | .01 |
| Allo-HSCT | 70 | 45 (37.5) | 25 (27.5) | .141 |
| CR1 | 24 | 15 | 9 | >.999 |
| ≥CR2 | 34 | 25 | 9 | .14 |
| Primary refractory | 12 | 5 | 7 | .1 |
| Variables . | Total (n = 280) . | Lower LGALS3 expression (n = 140) . | Higher LGALS3 expression (n = 140) . | P value . |
|---|---|---|---|---|
| Sex* | .81 | |||
| Male | 157 | 80 (51) | 77 (49) | |
| Female | 123 | 60 (48.8) | 63 (51.2) | |
| Age (years)† | 50 (15-90) | 45.5 (15-85) | 59 (15-90) | <.001 |
| Laboratory data† | ||||
| WBC (/μL) | 23 855 (650-423 000) | 28 390 (1530-324 000) | 21 810 (650-423 000) | .051 |
| Hemoglobin (g/dL) | 8 (3.3-16.2) | 8 (3.9-13.1) | 8.1 (3.3-16.2) | .664 |
| Platelet (×1000 /μL) | 45 (3-802) | 43 (5-712) | 46 (3-802) | .746 |
| Blast (/μL) | 12 621 (0-369 070) | 17 165 (0-245 592) | 7002 (0-369 070) | .002 |
| LDH (U/L) | 882 (274-13 130) | 1005 (284-13 130) | 792 (274-8116) | .011 |
| FAB* | ||||
| M0 | 5 | 3 (60) | 2 (40) | >.999 |
| M1 | 66 | 51 (77.3) | 15 (22.7) | <.001 |
| M2 | 98 | 52 (53.1) | 46 (46.9) | .531 |
| M4 | 84 | 30 (35.7) | 54 (64.3) | .003 |
| M5 | 16 | 2 (12.5) | 14 (87.5) | .003 |
| M6 | 4 | 2 (50) | 2 (50) | >.999 |
| Undetermined | 7 | 0 (0) | 7 (100) | .014 |
| Induction response*,‡ | 211 | 120 | 91 | |
| CR | 155 | 99 (82.5) | 56 (61.5) | .001 |
| PR | 8 | 5 (4.2) | 3 (3.3) | >.999 |
| Refractory | 34 | 13 (10.8) | 21 (23.1) | .023 |
| Induction death | 14 | 3 (2.5) | 11 (12.1) | .01 |
| Allo-HSCT | 70 | 45 (37.5) | 25 (27.5) | .141 |
| CR1 | 24 | 15 | 9 | >.999 |
| ≥CR2 | 34 | 25 | 9 | .14 |
| Primary refractory | 12 | 5 | 7 | .1 |
The median value of LGALS3 expression in total population was used as the cutoff point to define lower- and higher-expression groups.
PR, partial remission.
Number (%) of patients.
Median (range).
Only the 211 patients who received conventional intensive induction chemotherapy, and then consolidation chemotherapy if CR was achieved, were included in the analysis.